Treating Heparin Resistance With Antithrombin or Fresh Frozen Plasma

Annals of Thoracic Surgery

Volumn 85, Issue 6, 2008, Pages 2153-2160

  Spiess, Bruce D ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; FRESH FROZEN PLASMA; HEPARIN;

CARDIOPULMONARY BYPASS; DRUG SAFETY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTICOAGULANTS; ANTITHROMBINS; CARDIOPULMONARY BYPASS; DRUG RESISTANCE; HEART DISEASES; HEPARIN; PLASMA; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 43649096065     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2008.02.037     Document Type: Review

References (50)

1. Despotis G.J., Avidan M.S., and Hogue Jr. C.W. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 72 (2001) S1821-S1831
2. Paparella D., Brister S.J., and Buchanan M.R. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 30 (2004) 1873-1881
3. Rinder C. Cellular inflammatory response and clinical outcome in cardiac surgery. Curr Opin Anaesthesiol 19 (2006) 65-68
4. Bharadwaj J., Jayaraman C., and Shrivastava R. Heparin resistance. Lab Hematol 9 (2003) 125-131
5. Edmunds Jr. L.H., and Colman R.W. Thrombin during cardiopulmonary bypass. Ann Thorac Surg 82 (2006) 2315-2322
6. Avidan M.S., Levy J.H., Scholz J., et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 102 (2005) 276-284
7. Avidan M.S., Levy J.H., van Aken H., et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 130 (2005) 107-113
8. Ranucci M., Isgrò G., Cazzaniga A., et al. Different patterns of heparin resistance: therapeutic implications. Perfusion 17 (2002) 199-204
9. Staples M.H., Dunton R.F., Karlson K.J., Leonardi H.K., and Berger R.L. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg 57 (1994) 1211-1216
10. Williams M.R., D'Ambra A.B., Beck J.R., et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 70 (2000) 873-877
11. Ranucci M., Isgrò G., Cazzaniga A., Soro G., Menicanti L., and Frigiola A. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 14 (1999) 437-442
12. Hashimoto K., Yamagishi M., Sasaki T., Nakano M., and Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 58 (1994) 799-804
13. Cloyd G.M., D'Ambra M.N., and Akins C.W. Diminished anticoagulant response to heparin in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 94 (1987) 535-538
14. Dietrich W., Spannagl M., Schramm W., Vogt W., Barankay A., and Richter J.A. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 102 (1991) 505-514
15. Esposito R.A., Culliford A.T., Colvin S.B., Thomas S.J., Lackner H., and Spencer F.C. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. J Thorac Cardiovasc Surg 85 (1983) 346-353
16. Ranucci M., Frigiola A., Menicanti L., Ditta A., Boncilli A., and Brozzi S. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 33 (2005) 355-360
17. Sabbagh A.H., Chung G.K., Shuttleworth P., Applegate B.J., and Gabrhel W. Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass. Ann Thorac Surg 37 (1984) 466-468
18. Edmunds T., Van Patten S.M., Pollock J., et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 91 (1998) 4561-4571
19. Levy J.H., Weisinger A., Ziomek C.A., and Echelard Y. Recombinant antithrombin: production and role in cardiovascular disorder. Semin Thromb Hemost 27 (2001) 405-416
20. Barnette R.E., Shupak R.C., Pontius J., and Rao A.K. In vitro effect of fresh frozen plasma on the activated coagulation time in patients undergoing cardiopulmonary bypass. Anesth Analg 67 (1988) 57-60
21. Leong C.K., and Ong B.C. A case report of heparin resistance due to acquired antithrombin III deficiency. Ann Acad Med Singapore 27 (1998) 877-879
22. Despotis G.J., Levine V., Alsoufiev A., Joist H., Goodnough L.T., and Pasque M. Recurrent thrombosis of biventricular-support devices associated with accelerated intravascular coagulation and increased heparin requirements. J Thorac Cardiovasc Surg 112 (1996) 538-540
23. Soloway H.B., and Christiansen T.W. Heparin anticoagulation during cardiopulmonary bypass in an antithrombin-III deficient patient. Implications relative to the etiology of heparin rebound. Am J Clin Pathol 73 (1980) 723-725
24. Levy J.H., Montes F., Szlam F., and Hillyer C.D. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 90 (2000) 1076-1079
25. Van Norman G.A., Gernsheimer T., Chandler W.L., Cochran R.P., and Spiess B.D. Indicators of fibrinolysis during cardiopulmonary bypass after exogenous antithrombin-III administration for acquired antithrombin III deficiency. J Cardiothorac Vasc Anesth 11 (1997) 760-763
26. Kanbak M. The treatment of heparin resistance with antithrombin III in cardiac surgery. Can J Anaesth 46 (1999) 581-585
27. Brown M.E., Gallagher J.M., and Armitage J.M. The use of antithrombin III concentrate for treatment of heparin resistance during cardiopulmonary bypass. J Extra Corpor Technol 32 (2000) 75-78
28. Irani M.S. Antithrombin concentrates in heparin-resistant cardiopulmonary bypass patients. Clin Appl Thromb Hemost 2 (1996) 103-106
29. Conley J.C., and Plunkett P.F. Antithrombin III in cardiac surgery: an outcome study. J Extra Corpor Technol 30 (1998) 178-183
30. Lemmer Jr. J.H., and Despotis G.J. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 123 (2002) 213-217
31. Koster A., Fischer T., Gruendel M., et al. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation. J Cardiothorac Vasc Anesth 17 (2003) 171-175
32. Despotis G.J., Gravlee G., Filos K., and Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 91 (1999) 1122-1151
33. Casbard A.C., Williamson L.M., Murphy M.F., Rege K., and Johnson T. The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia 59 (2004) 550-558
34. Stanworth S.J., Brunskill S.J., Hyde C.J., McClelland D.B., and Murphy M.F. Is fresh frozen plasma clinically effective?. A systematic review of randomized controlled trials. Br J Haematol 126 (2004) 139-152
35. Warkentin T.E. Anticoagulation for cardiopulmonary bypass: is a replacement for heparin on the horizon?. J Thorac Cardiovasc Surg 131 (2006) 515-516
36. Stramer S.L., Fang C.T., Foster G.A., Wagner A.G., Brodsky J.P., and Dodd R.Y. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 353 (2005) 451-459
37. Hoffman D.L. Purification and large-scale preparation of antithrombin III. Am J Med 87 Suppl 3B (1989) 23S-26S
38. Morrica A., Nardini C., Falbo A., Bailey A.C., and Bucci E. Manufacturing process of anti-thrombin III concentrate: viral safety validation studies and effect of column re-use on viral clearance. Biologicals 31 (2003) 165-173
39. Schwartz R.S., Bauer K.A., Rosenberg R.D., Kavanaugh E.J., Davies D.C., Bogdanoff D.A., and The Antithrombin III Study Group. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. Am J Med 87 Suppl 3B (1989) 53S-60S
40. Menache D., O'Malley J.P., Schorr J.B., et al., Cooperative Study Group. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 75 (1990) 33-39
41. Preiss D.U., Abdullah D., Eberspächer B., and Wilhelm K. Safety of virus inactivated antithrombin III concentrate antithrombin III immuno (AT III). Thromb Res 65 (1992) 677-686
42. Bucur S.Z., Levy J.H., Despotis G.J., Spiess B.D., and Hillyer C.D. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 38 (1998) 481-498
43. Covin R., O'Brien M., Grunwald G., et al. Factors affecting transfusion of fresh frozen plasma, platelets, and red blood cells during elective coronary artery bypass graft surgery. Arch Pathol Lab Med 127 (2003) 415-423
44. Bux J. Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion. Vox Sang 89 (2005) 1-10
45. Gajic O., and Moore S.B. Transfusion-related acute lung injury. Mayo Clin Proc 80 (2005) 766-770
46. Holness L., Knippen M.A., Simmons L., and Lachenbruch P.A. Fatalities caused by TRALI. Transfus Med Rev 18 (2004) 184-188
47. Looney M.R., Gropper M.A., and Matthay M.A. Transfusion-related acute lung injury: a review. Chest 126 (2004) 249-258
48. Toy P., Popovsky M.A., Abraham E., et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 33 (2005) 721-726
49. Rana R., Fernández-Pérez E.R., Khan S.A., et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion 46 (2006) 1478-1483
50. Red Book. 2006 ed. (2006), Thomson PDR, Montvale, NJ :678.